65,437 trials
Primary Myelofibrosis · Thrombocytosis · Essential Thrombocythemia
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) (Phase 1b) — 0; 2; 0; 1 Participants
Hernia, Inguinal
Primary: Operating Time From Skin Incision to Wound Closure — 39.2; 47.7 minutes
Colorectal Cancer
Primary: Maximum Tolerated Dose (MTD) of Azacitidine, and Capecitabine and Oxaliplatin (CAPOX) — 75; 110; 1500 mg/m^2
Leukemia
Primary: Participants With a Response — 12; 19 Participants
Frontal Lobe Hypometabolism
Primary: Global Change in Brain Glucose Uptake — 30.3; 30.4 μmol/100 g/min
Liver Cancer
Primary: Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) — 1; 1; 17; 15 Participants
Duchenne Muscular Dystrophy
Primary: Number of Dose Limiting Toxicity (DLT) Adverse Events as Assessed by 21 CFR 312.32. — 0 Number of Events
Respiratory Syncytial Virus Infections
Primary: Number of Subjects With Any and Grade 3 Solicited Local Adverse Events (AE) During a 7-day Follow-up Period — 59; 64; 67; 20 Participants
Myofascial Pain Syndrome of Neck
Primary: Visual Analog Scale (VAS) Score Change — 5.9; 5.1; 4.1; 2.3 score on a scale
Klinefelter Syndrome
Primary: Change in Body Fat Percent Z-score — -0.12; 0.92 score on a scale
Post-Op Complication
Primary: Infants With Elevated s100b and NSE — 11; 9 Participants
Tobacco Dependence · PTSD
Primary: Percentage of Participants Who Abstained From Smoking — 23; 21; 20; 19 Participants
Plasmodium Falciparum Malaria
Primary: Activity of SJ733 Administered Orally on Clearance of P. Falciparum Blood Stage Parasites From the Blood in Healthy Subjects (Men and WNCBP) — 172; 11551 Parasite…
Myofascial Trigger Point Pain (MTrP)
Primary: Pain Pressure Threshold (PPT) — 1.4; 1.4; 1.6; 1.6 Kg/cm2
Spinal Cord Injury
Primary: Pinch Force — 8.7; 10.6 newtons